Trial Profile
An Open-Label Phase 2 Study of Intravenous Bortezomib and Oral Panobinostat (LBH589) in Adult Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma or NK/T-Cell Lymphoma After Failure of Conventional Chemotherapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Panobinostat (Primary)
- Indications Extranodal NK-T-cell lymphoma; Peripheral T-cell lymphoma
- Focus Therapeutic Use
- 07 Jun 2011 Trial design presented at the 47th Annual Meeting of the American Society of Clinical Oncology. Five patients have been enrolled to date.
- 14 Nov 2009 Actual initiation date (1 Nov 2009) added as reported by ClinicalTrials.gov.
- 14 Nov 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.